Clinical Research – My Ketamine Home

24 September 2019

Ketamine effects on default mode network activity and vigilance: A randomized, placebo‐controlled crossover simultaneous fMRI/EEG study

In resting‐state functional connectivity experiments, a steady state (of consciousness) is commonly supposed. However, recent research has shown that the resting state is a rather dynamic than a steady state. In particular, changes of vigilance appear to play a prominent role. Accordingly, it is critical to assess the state of vigilance when conducting pharmacodynamic studies …

Ketamine effects on default mode network activity and vigilance: A randomized, placebo‐controlled crossover simultaneous fMRI/EEG study Read More »

Learn more

24 September 2019

Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far

Depression, one of the most common mental health disorders, is among the leading causes of health-related disability worldwide. Although antidepressant treatment has been available for decades, depression remains largely refractory to the prevailing limited treatment approach of monoamine transmission modulation. Fortunately, recent evidence points to a link between depression and inflammatory factors within the innate …

Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far Read More »

Learn more

6 June 2019

Toward specific ways to combine ketamine and psychotherapy in treating depression

In major depression, remission rate in response to monoaminergic antidepressant is around 50%. The lack of strong synergies between classical antidepressants and psychotherapy may be due to the molecular effects of classical antidepressants. They modulate synapses but they do not substantially influence synaptogenesis. They also increase brain-derived neurotrophic factor (BDNF). However, for activity-dependent plasticity, BDNF …

Toward specific ways to combine ketamine and psychotherapy in treating depression Read More »

Learn more

24 March 2019

Ketamine: A Paradigm Shift for Depression Research and Treatment

Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy shed new light on the mechanisms underlying antidepressant efficacy.

Learn more

6 March 2019

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy

Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine’s psychedelic effects are viewed as undesirable “side …

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy Read More »

Learn more

24 January 2019

Neurophysiological Correlates and Differential Drug Response in Subjects With a Family History of an Alcohol Use Disorder

A family history of an alcohol use disorder (AUD) has been shown to increase one’s risk of developing an AUD. Additionally, a positive family history of AUD (family history positive (FHP)) has neurobiological and neuropsychopharmacological consequences, and this review summarizes differential drug response as well as neuroanatomical and neurocognitive correlates. FHP status is related to …

Neurophysiological Correlates and Differential Drug Response in Subjects With a Family History of an Alcohol Use Disorder Read More »

Learn more

24 October 2018

The Neurobiology of Depression, Ketamine and Rapid-Acting Antidepressants: Is it Glutamate Inhibition or Activation?

The discovery of the antidepressant effects of ketamine has opened a breakthrough opportunity to develop a truly novel class of safe, effective, and rapid-acting antidepressants (RAADs). In addition, the rapid and robust biological and behavioral effects of ketamine offered a unique opportunity to utilize the drug as a tool to thoroughly investigate the neurobiology of …

The Neurobiology of Depression, Ketamine and Rapid-Acting Antidepressants: Is it Glutamate Inhibition or Activation? Read More »

Learn more

24 June 2018

Personalized (N-of-1) Trials for Depression: A Systematic Review

Five eligible studies reporting on 47 depressed patients (range, 1-18 patients) were identified. Two studies were conducted among adults with treatment-resistant depression, 1 study among depressed inpatients, and 2 studies among patients from special populations (geriatric nursing home, human immunodeficiency virus-associated encephalopathy). All studies evaluated the effects of pharmacologic treatments (methylphenidate, D-amphetamine, ketamine, and sulpiride). …

Personalized (N-of-1) Trials for Depression: A Systematic Review Read More »

Learn more

24 June 2018

The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects

The ability of ketamine administration to activate prefrontal glutamate neurotransmission is thought to be a key mechanism contributing to its transient psychotomimetic effects and its delayed and sustained antidepressant effects. Rodent studies employing carbon-13 magnetic resonance spectroscopy (13C MRS) methods have shown ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists to transiently increase measures reflecting glutamate–glutamine …

The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects Read More »

Learn more

6 June 2018

The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects

The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects Read More »

Learn more

FILTER BY

Ketamine effects on default mode network activity and vigilance: A randomized, placebo‐controlled crossover simultaneous fMRI/EEG study

Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far

Toward specific ways to combine ketamine and psychotherapy in treating depression

Ketamine: A Paradigm Shift for Depression Research and Treatment

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy

Neurophysiological Correlates and Differential Drug Response in Subjects With a Family History of an Alcohol Use Disorder

The Neurobiology of Depression, Ketamine and Rapid-Acting Antidepressants: Is it Glutamate Inhibition or Activation?

Personalized (N-of-1) Trials for Depression: A Systematic Review

The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects

The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects

TAKE THE FIRST STEP

A True Breakthrough In Mental Health

How It Works

About

Resources